The ailing antibiotics market

One of the most worrying corporate failures of this decade is the announced bankruptcy of a US pharmaceutical company. The tragedy is not only that investors have lost their money. It is a signal that there is no viable route to market for new antibiotics treating superbugs, however valuable they are to contemporary life.